Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.
Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.
Cantor’s Mara Goldstein may be playing it cautious on Celgene, but she still spotlights 8% upside potential for this biotech player.
Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) gave investors reason to raise a red flag today, as shares start to slip …
Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective …
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
Eric Schmidt worries CELG investors will further question franchises’ longevity in the 3Q earnings aftermath.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
